bioscience schreef op 17 december 2013 12:46:
13,41 laag - 20,63 hoog// koers ontwikkeling 1 jaar // huidige koers 14
Dus na een jaar van zeer vele mooie ontwikkelingen /nieuws , staan we bijna op de laagste stand van het jaar .
Dan durven er nog mensen te beweren dat we niet ondergewaardeerd zijn ?
Press Releases 2013
December 16, 2013
Galapagos selects pre-clinical candidate for cystic fibrosis
View English version - Bekijk Nederlandse versie
December 6, 2013
Galapagos increases share capital through warrant exercises
View English version - Bekijk Nederlandse versie
December 4, 2013
Galapagos reports positive Phase 1 results for GLPG1205
View English version - Bekijk Nederlandse versie
November 27, 2013
Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis
View English version - Bekijk Nederlandse versie
November 20, 2013
Galapagos announces that BioFocus has signed an integrated drug discovery collaboration with Boehringer Ingelheim
View English version - Bekijk Nederlandse versie
November 15, 2013
Galapagos business update
View English version - Bekijk Nederlandse versie
November 12, 2013
Galapagos subsidiary BioFocus signs agreement with Biogen Idec in scleroderma
View English version - Bekijk Nederlandse versie
October 21, 2013
Galapagos increases share capital through warrant exercises
View English version - Bekijk Nederlandse versie
October 17, 2013
Galapagos presents superior potentiator series for CF
View English version - Bekijk Nederlandse versie
October 16, 2013
Galapagos to present Phase 1 data on FFA2 antagonist GLPG0974 at UEG Week in Berlin
View English version - Bekijk Nederlandse versie
October 16, 2013
Galapagos to present GLPG0634 at ACR
View English version - Bekijk Nederlandse versie
September 30, 2013
Delta Lloyd notify of 9.93% shareholding in Galapagos
View English version - Bekijk Nederlandse versie
September 24, 2013
AbbVie and Galapagos to co-develop cystic fibrosis therapies
View English version - Bekijk Nederlandse versie
September 18, 2013
Galapagos creates new warrant plan
View English version - Bekijk Nederlandse versie
August 20, 2013
Galapagos appoints David Smith as CEO of Service Division
View English version - Bekijk Nederlandse versie
August 9, 2013
Galapagos announces half year results 2013
View English version - Bekijk Nederlandse versie
July 23, 2013
Galapagos delivers novel osteoarthritis molecules in alliance with Servier
View English version - Bekijk Nederlandse versie
July 8, 2013
Galapagos receives €2.4 million IWT grant for psoriasis research
View English version - Bekijk Nederlandse versie
July 2, 2013
Galapagos initiates Phase 1 trial as part of its alliance with Janssen Pharmaceutica NV
View English version - Bekijk Nederlandse versie
July 1, 2013
Galapagos increases share capital through warrant exercises
View English version - Bekijk Nederlandse versie
July 1, 2013
First patients screened for Phase 2B studies with GLPG0634
View English version - Bekijk Nederlandse versie
June 13, 2013
Galapagos presents GLPG0634 at EULAR poster session
View English version - Bekijk Nederlandse versie
May 17, 2013
Galapagos creates new warrant plan
View English version - Bekijk Nederlandse versie
May 17, 2013
AbbVie and Galapagos extend GLPG0634 collaboration to include Crohn's disease
View English version - Bekijk Nederlandse versie
May 17, 2013
Galapagos business update
View English version - Bekijk Nederlandse versie
May 13, 2013
Galapagos to present three posters on GLPG0634 at EULAR
View English version - Bekijk Nederlandse versie
April 30, 2013
NYSE Liffe lists Equity Options on Galapagos
View English version - Bekijk Nederlandse versie
April 29, 2013
Galapagos completes private placement by issuance of 2,696,831 new ordinary shares
View English version - Bekijk Nederlandse versie
April 24, 2013
Galapagos raises €54 million
View English version - Bekijk Nederlandse versie
April 24, 2013
Galapagos to raise capital via a private placement of new shares
View English version - Bekijk Nederlandse versie
April 23, 2013
Galapagos starts Phase 2A study with GLPG0974 in ulcerative colitis
View English version - Bekijk Nederlandse versie
April 22, 2013
Galapagos discovers novel candidate drug to treat breast cancer
View English version - Bekijk Nederlandse versie
April 16, 2013
Galapagos presents scope of GLPG0634 Phase 2b program
View English version - Bekijk Nederlandse versie
April 12, 2013
Gestion notify of 4.97% shareholding in Galapagos
View English version - Bekijk Nederlandse versie
April 8, 2013
Galapagos increases share capital through warrant exercises
View English version - Bekijk Nederlandse versie
March 27, 2013
Galapagos to start Phase 2a study with GLPG0974 in IBD patients
View English version - Bekijk Nederlandse versie
March 27, 2013
Galapagos gives R&D Update
View webcast presentation
View English version - Bekijk Nederlandse versie
March 20, 2013
Galapagos to host annual R&D Update on 27 March
View English version - Bekijk Nederlandse versie
March 8, 2013
Galapagos reports record revenues in 2012, increasing momentum in clinical pipeline
View webcast presentation
View English version - Bekijk Nederlandse versie
View Financial Tables - Bekijk Financiële Tabellen
March 8, 2013
Galapagos and Roche conclude strategic alliance
View English version - Bekijk Nederlandse versie
March 6, 2013
Galapagos receives €7.5 million in Servier alliances
View English version - Bekijk Nederlandse versie
March 4, 2013
Katrine Bosley appointed to Galapagos' Board of Directors
View English version - Bekijk Nederlandse versie
February 5, 2013
Galapagos announces GSK2586184 JAK1 molecule progresses to Phase 2 studies
View English version - Bekijk Nederlandse versie
January 30, 2013
Galapagos receives €2.5 million IWT grant for IBD research
View English version - Bekijk Nederlandse versie
January 16, 2013
Galapagos delivers candidate drug in its alliance with Janssen Pharmaceutica NV and receives €4 million milestone payment
View English version - Bekijk Nederlandse versie
January 15, 2013
Galapagos acquires Cangenix, a structure-based drug discovery company
View English version - Bekijk Nederlandse versie
January 15, 2013
Galapagos creates Fidelta, a third Galapagos service division
View English version - Bekijk Nederlandse versie
January 10, 2013
Galapagos receives €2.7 million IWT grant for antibacterial research
View English version - Bekijk Nederlandse versie
January 9, 2013
Galapagos delivers candidate drug in GSK alliance and receives milestone payment
View English version - Bekijk Nederlandse versie
January 6, 2013
Galapagos to present at the 31st annual J. P. Morgan Healthcare Conference